Dupilumab for the treatment of refractory lenalidomide rash in patients with multiple myeloma

被引：3
|
作者：
Kuo, Alyce M. [1 ]
Hassoun, Hani [2 ]
Shah, Urvi [2 ]
Gordon, Allison [1 ]
Hollmann, Travis J. [3 ]
Landau, Heather J. [4 ]
Lezcano, Cecilia [3 ]
Mailankody, Sham [2 ]
Tan, Carlyn C. [2 ]
Lesokhin, Alexander M. [2 ]
Markova, Alina [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Dermatol Serv, 545 E 73rd St, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, New York, NY USA
[3] Mem Sloan Kettering Canc Ctr, Dept Pathol, Dermatopathol Serv, New York, NY USA
[4] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, New York, NY USA
来源：
LEUKEMIA & LYMPHOMA | 2022年 / 63卷 / 09期
关键词：
CELLS; SKIN;
D O I：
10.1080/10428194.2022.2068002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2233 / 2237
页数：5
相关论文
共 50 条
  • [31] Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
    David S. Siegel
    Gary J. Schiller
    Christy Samaras
    Michael Sebag
    Jesus Berdeja
    Siddhartha Ganguly
    Jeffrey Matous
    Kevin Song
    Christopher S. Seet
    Giampaolo Talamo
    Mirelis Acosta-Rivera
    Michael Bar
    Donald Quick
    Bertrand Anz
    Gustavo Fonseca
    Donna Reece
    William E. Pierceall
    Weiyuan Chung
    Faiza Zafar
    Amit Agarwal
    Nizar J. Bahlis
    Leukemia, 2020, 34 : 3286 - 3297
  • [32] Lenalidomide plus dexamethasone demonstrates efficacy in the treatment of relapsed or refractory multiple myeloma
    不详
    FORMULARY, 2008, 43 (02) : 79 - 80
  • [33] Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myeloma
    Takashi Yoshida
    Masaki Ri
    Haruna Fujinami
    Yoshiko Oshima
    Takuto Tachita
    Yoshiaki Marumo
    Hirokazu Sasaki
    Shiori Kinoshita
    Haruhito Totani
    Tomoko Narita
    Ayako Masaki
    Asahi Ito
    Shigeru Kusumoto
    Takashi Ishida
    Hirokazu Komatsu
    Shinsuke Iida
    International Journal of Hematology, 2019, 110 : 228 - 236
  • [34] LONG TERM TREATMENT WITH LENALIDOMIDE-DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Rocchi, S.
    Petrucci, M. T.
    Zambello, R.
    Montefusco, V.
    Pantani, L.
    Gamberi, B.
    Rizzello, I.
    Nozzoli, C.
    Dozza, L.
    Borsi, E.
    De Paoli, L.
    Palmieri, S.
    Cellini, C.
    di Toritto, T. Caravita
    Tosi, P.
    Morabito, F.
    Gozzetti, A.
    Cavo, M.
    HAEMATOLOGICA, 2017, 102 : 129 - 130
  • [35] Combination of ixazomib, pomalidomide and dexamethasone in the treatment of multiple myeloma in relapse and refractory to lenalidomide
    Stocker, Nicolas
    HEMATOLOGIE, 2018, 24 (04): : 261 - 262
  • [36] Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
    Siegel, David S.
    Schiller, Gary J.
    Samaras, Christy
    Sebag, Michael
    Berdeja, Jesus
    Ganguly, Siddhartha
    Matous, Jeffrey
    Song, Kevin
    Seet, Christopher S.
    Talamo, Giampaolo
    Acosta-Rivera, Mirelis
    Bar, Michael
    Quick, Donald
    Anz, Bertrand
    Fonseca, Gustavo
    Reece, Donna
    Pierceall, William E.
    Chung, Weiyuan
    Zafar, Faiza
    Agarwal, Amit
    Bahlis, Nizar J.
    LEUKEMIA, 2020, 34 (12) : 3286 - 3297
  • [37] REAL-WORLD EXPERIENCE OF LENALIDOMIDE/DEXAMETHASONE TREATMENT FOR REFRACTORY/RELAPSED MULTIPLE MYELOMA (RRMM) PATIENTS
    Tognazzi, L.
    Rivolti, E.
    Quaresima, M.
    Labbozzetta, S.
    Gamberi, B.
    Merli, F.
    HAEMATOLOGICA, 2017, 102 : 137 - 137
  • [38] Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myeloma
    Yoshida, Takashi
    Ri, Masaki
    Fujinami, Haruna
    Oshima, Yoshiko
    Tachita, Takuto
    Marumo, Yoshiaki
    Sasaki, Hirokazu
    Kinoshita, Shiori
    Totani, Haruhito
    Narita, Tomoko
    Masaki, Ayako
    Ito, Asahi
    Kusumoto, Shigeru
    Ishida, Takashi
    Komatsu, Hirokazu
    Iida, Shinsuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 110 (02) : 228 - 236
  • [39] Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
    M A Dimopoulos
    A S Swern
    J S Li
    M Hussein
    L Weiss
    Y Nagarwala
    R Baz
    Blood Cancer Journal, 2014, 4 : e257 - e257
  • [40] Low-dose lenalidomide and dexamethasone combination treatment in elderly patients with relapsed and refractory multiple myeloma
    Wang, Chunling
    He, Zhengmei
    Shi, Yuye
    Zhang, Lijuan
    Chen, Yue
    Chen, Zhi
    Yu, Liang
    HEMATOLOGY, 2017, 22 (02) : 88 - 92
12345